Stock Pulse
Moderna experienced a significant 31.8% stock decline in Q1 2025 due to plummeting post-pandemic sales of COVID-19 and RSV vaccines, leading to lowered revenue projections and cost-cutting measures [6]. Despite receiving its first non-COVID mRNA vaccine approval in Australia for RSV [5], Q4 2024 revenues were down 65.6% year-over-year, meeting expectations but with weak full-year guidance [7]. Moderna will report Q1 2025 earnings on May 1st [2]. While the company is presenting twelve diverse research projects at the ESCMID 2025 Global Congress [8], the resignation of a key FDA official adds uncertainty [6], [10]. Potential indirect benefits may arise from competitor Novavax's struggles with FDA approval [1], but hypothetical risks exist regarding potential regulatory changes under a second Trump administration [3].